The performance trial of the Covid-19 antibody testing kit developed by Gonoshasthaya Kendra is complete.
The Bangabandhu Sheikh Mujib Medical University (BSMMU) is going to present the trial results to the Directorate General of Drug Administration (DGDA) soon.
The BSMMU Vice-Chancellor Professor Kanak Kanti Barua confirmed this to The Business Standard.
"We have already conducted a performance trial. Also, we are almost done with data processing and preparing the final report. Once that is finished, we will submit the final report."
Replying to a query, he said, "We have not yet set the date of submission. When I get the final report from the committee that conducted the performance study, I will announce the date."
However, Kanak Kanti earlier told UNB that Professor Shahina Tabassum, head of the committee formed to conduct the performance study, informed him that they would submit the report to the DGDA within a day or two.
Kanak Kanti also said, "We are not going to make a report on Gonoshasthaya's Covid-19 antigen testing kit as the organisation withdrew it on June 2."
The antibody kit will help identify whether people have already contracted Covid-19, and the individual has a presence of antibodies or resistance power in their bodies, according to Gonoshasthaya.
It will also help collect the plasma of those who have recovered.
In a press release issued on June 2, the organisation requested BSMMU suspend the performance study of its Covid-19 antigen testing kit due to the detection of some inconsistencies in the sample collection procedure.
The organisation added that it was upgrading the sample collection process.
On March 17, Gonoshasthaya announced that they developed a testing kit that could examine samples to detect Covid-19 within 15 minutes, but they had yet to get the approval of the authorities concerned.
On April 30, the DGDA allowed the organisation to get its kits tested. Later, the BSMMU started conducting performance trials of the kit.